The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer

被引：1
|
作者：
Tripathy, Sambit [1 ]
机构：
[1] AIIMS, Dept Urol, Bhubaneswar, Odisha, India
来源：
INDIAN JOURNAL OF UROLOGY | 2021年 / 37卷 / 03期
关键词：
D O I：
10.4103/iju.IJU_542_20
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：293 / 294
页数：2
相关论文
共 50 条
  • [1] Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
    Roumiguie, Mathieu
    Paoletti, Xavier
    Neuzillet, Yann
    Mathieu, Romain
    Vincendeau, Sebastien
    Kleinclauss, Francois
    Mejean, Arnaud
    Guy, Laurent
    Timsit, Marc Olivier
    Lebret, Thierry
    FUTURE ONCOLOGY, 2021, 17 (14) : 1811 - 1823
  • [2] Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
    Cattrini, Carlo
    Caffo, Orazio
    De Giorgi, Ugo
    Mennitto, Alessia
    Gennari, Alessandra
    Olmos, David
    Castro, Elena
    CANCERS, 2022, 14 (07)
  • [3] Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Halabi, Susan
    Jiang, Shan
    Terasawa, Emi
    Garcia-Horton, Viviana
    Ayyagari, Rajeev
    Waldeck, A. Reginald
    Shore, Neal
    JOURNAL OF UROLOGY, 2021, 206 (02): : 298 - 307
  • [4] Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial
    Fizazi, K.
    Blue, Ian
    Nowak, Joel T.
    FUTURE ONCOLOGY, 2021, 17 (14) : 1 - 9
  • [5] ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 2 - 5
  • [6] ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris Y.
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
    Carles, Joan
    Medina-Lopez, Rafael A.
    Puente, Javier
    Gomez-Ferrer, Alvaro
    Nebra, Javier Casas
    Medina, Maria Isabel Saez
    Ribal, Maria J.
    Antolin, Alfredo Rodriguez
    Alvarez-Ossorio, Jose Luis
    Novo, Jose Francisco Suarez
    Agut, Cristina Moretones
    Srinivasan, Shankar
    Ortiz, Jorge
    Fizazi, Karim
    FUTURE ONCOLOGY, 2023, 19 (12) : 819 - 828
  • [8] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1235 - 1246
  • [9] Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Le Berre, Marie-Aude
    Petrenciuc, Oana
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (11): : 1040 - 1049
  • [10] Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2019, 202 (04): : 660 - 661
12345